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Temporal changes in mouse aortic wall gene
expression during the development of
elastase-induced abdominal aortic aneurysms
Sarah J. Van Vickle-Chavez, BA,a William S. Tung, MD,a Tarek S. Absi, MD,a Terri L. Ennis, BS,a
Dongli Mao, MD,a J. Perren Cobb, MD,a and Robert W. Thompson, MD,a,b,c St Louis, Mo
Objective: To characterize temporal changes in mouse aortic wall gene expression associated with the development of
experimental abdominal aortic aneurysms.
Methods: C57BL/6 mice underwent transient perfusion of the abdominal aorta with either elastase (n  61) or
heat-inactivated elastase as a control (n  68). Triplicate samples of radiolabeled aortic wall complementary DNA were
prepared at intervals of 0, 3, 7, 10, and 14 days, followed by hybridization to nylon microarrays (1181 genes).
Autoradiographic intensity data were normalized by conversion to z scores, and differences in gene expression were
defined by two-tailed z tests at a significance threshold of P < .01.
Results: Elastase perfusion caused a progressive increase in aortic diameter up to 14 days accompanied by transmural
inflammation and destructive remodeling of the elastic media. No aneurysms occurred in the control group. Compared with
healthy aorta, 336 genes exhibited significant alterations during at least 1 interval after elastase perfusion (135 at more than
1 interval and 14 at all intervals), with pronounced increases for interleukin 6, cyclin E2, interleukin 1, osteopontin,
CD14/lipopolysaccharide receptor, P-selectin glycoprotein ligand 1, and gelatinase B/matrix metalloproteinase 9 (all
>20-fold on day 3). Sixty-two genes exhibited synchronous alterations in the elastase and control groups, thus suggesting a
nonspecific response. By direct comparisons between the elastase and control groups, there were 384 genes with significant
differences in expression for at least 1 interval after aortic perfusion, including 234 with differential upregulation (eg,
p44MAPK/ERK1, osteopontin, heat shock protein 84, hypoxia-inducible factor 1, apolipoproteinE,monocyte chemotactic
protein 3, MIG (monokine induced by gamma interferon), and interleukin 2 receptor ) and 163 with differential
downregulation (eg, prothrombin, granzyme B, ataxia telangiectasia mutated, and interleukin-converting enzyme).
Conclusions: Development of elastase-induced abdominal aortic aneurysms in mice is accompanied by altered aortic wall
expression of genes associated with acute and chronic inflammation, matrix degradation, and vascular tissue remodeling.
Knowledge of these alterations will facilitate further studies on the functional molecular mechanisms that underlie
aneurysmal degeneration. (J Vasc Surg 2006;43:1010-20.)Understanding the cellular and molecular mechanisms
that underlie the development of abdominal aortic aneu-
From the Departments of Surgery,a Radiology,b and Cell Biology and
Physiology,c Washington University School of Medicine.
Supported by grants R01 HL64332 and R01 HL64333 from the National
Heart, Lung, and Blood Institute (RWT) and by an award for Excellence
in Vascular Surgical Research for Residents, Fellows, and Mentors from
the William J. von Liebig Foundation. JPC was supported by the George
H. A. Clowes, Jr, Memorial Research Career Development Award from
the American College of Surgeons and by grant R01GM059960 from the
National Institute for General Medical Sciences.
Competition of interest: Dr Thompson has previously received research
project grant support from Medtronic, Inc (Santa Rosa, Calif) and from
Cordis/Johnson & Johnson for research projects unrelated to this article.
Presented at the Second American Heart Association Conference on Arterio-
sclerosis, Thrombosis, and Vascular Biology, Arlington, Va,May 11-13, 2001.
Reprint requests: Robert W. Thompson, MD, Section of Vascular Surgery,
Washington University School of Medicine, 9901 Wohl Hospital, 4960
Children’s Place, St Louis, MO 63110 (e-mail: thompsonr@msnotes.
wustl.edu).
0741-5214/$32.00
Copyright © 2006 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2006.01.004
1010rysms (AAAs) remains an active area of interest. To better
elucidate the molecular changes that occur in AAAs, com-
plementary DNA (cDNA) microarrays have been used to
profile differences in gene expression between normal hu-
man aorta and aneurysm tissues.1-3 Although this approach
provides insight into the genes expressed in end-stage
humanAAA tissues, it is unclear how these alterations relate
to the dynamic processes involved in earlier or progressive
stages of disease. An alternative approach to address this
question is by examining aortic wall gene expression in
experimental animal models of AAAs, which have already
provided a useful means of investigating the pathophysio-
logic mechanisms that underlie aneurysmal degeneration.4,5
Transient aortic perfusion with pancreatic elastase is
one of the most widely used experimental models of
AAAs.4,5 Although elastase perfusion does not immediately
result in aneurysm formation, it initiates a process of aortic
wall infiltration by mononuclear phagocytes, increased lo-
cal expression of endogenous proteinases, progressive elas-
tin degradation, and gradual aortic wall dilation.6,7 Because
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panied by histopathologic changes that mirror those found
in human AAAs, elastase-induced AAAs have been used to
demonstrate the functional importance of proinflammatory
cytokines, prostaglandins, and matrix metalloproteinases
(MMPs) in aneurysm disease, as well as effective suppres-
sion of AAAs by using various anti-inflammatory agents and
proteinase inhibitors.8-11 Adaptation of this model to ge-
netically altered mice has also made it possible to delineate
the functional importance of specific gene products in the
process of aneurysm formation.12-15
Given the potential insights into disease mechanisms
that might be obtained through more comprehensive un-
derstanding of the elastase-induced mouse model of AAAs,
we sought, by use of cDNA microarray techniques, to
systematically characterize the temporal alterations in aortic
wall gene expression that accompany aneurysm develop-
ment. Our results confirm that experimental AAAs involve
altered patterns of expression for many genes associated
with acute and chronic inflammation, matrix degradation,
and vascular tissue remodeling, as well as several matricel-
lular glycoproteins not previously associated with aneurysm
disease. This systematic approach has thereby helped to
identify regulatory pathways and putative therapeutic tar-
gets in aneurysmal degeneration, thus providing an impor-
tant basis for further investigation.
METHODS
A complete description of all methods is provided online.
Elastase perfusion model. All experimental proce-
dures were performed in accord with a protocol approved
by the Animal Studies Committee at Washington Univer-
sity School ofMedicine. Adult male C57BL/6Jmice (Jack-
son Laboratory, Bar Harbor, Me) were subjected to tran-
sient intraluminal perfusion of the infrarenal aorta with
either elastase (n  61) or heat-inactivated elastase for
controls (n  68), as previously described.12,16
Radiolabeled cDNA probes and membrane hybri-
dization. Animals were killed on days 3, 7, 10, and 14 after
perfusion with elastase or heat-inactivated elastase, along
with additional mice to provide normal aortic tissues. Aor-
tic tissues were snap-frozen at 70 °C and divided into
three equal subgroups for each experimental condition, and
the tissues for each subgroup were pooled as triplicate
samples (each pool contained up to eight aortic specimens).
All subsequent steps were thereafter performed by using
triplicate samples for each experimental condition for a
total of 27 separate microarrays. Pooled aortic tissue sam-
ples were pulverized under liquid nitrogen, total RNA was
isolated, and 33P-labeled cDNA probes were prepared with
reagents and protocols provided with the Atlas Mouse
1.2 cDNA Expression Array kit from Clontech Laborato-
ries, Inc (Palo Alto, Calif). Each labeled cDNA probe
sample was incubated with a nylon membrane containing
cDNA clones corresponding to 1181 known murine genes
(AtlasArray Mouse 1.2; Clontech). After autoradiography,
densitometry readings for each gene were adjusted for
background readings on the same membrane.Data analysis and estimates of statistical significance.
Densitometry signal intensities were transformed to z
scores to normalize the data from each microarray.17 The
average z score was determined for each gene at each time
interval for each of the experimental groups. The signifi-
cance of differences in gene expression was evaluated by
using the two-sample-for-means z test to maximize the
power of replicates and to take into account variation
between replicates on a gene-by-gene basis.17 P values were
assigned to the calculated z test values, and the threshold
for statistical significance was set at P .01 for all compar-
isons between groups. The n-fold changes in gene expres-
sion were calculated, and temporal changes in gene expres-
sion were plotted for selected genes by using the mean 
SE of converted z-score values.
RESULTS
Time course of aneurysm development. There was a
moderate increase in mouse aortic diameter (AD) (approx-
imately 50%) immediately after perfusion with either elas-
tase or heat-inactivated elastase, but in no case did this
reach aneurysmal proportions (Fig 1,A and Table A, online
only). In the elastase-perfused group, there was a gradual
increase in AD between days 3 and 10, followed by more
rapid dilatation between days 10 and 14. In contrast, AD
remained stable throughout the 14-day experimental pe-
riod in the control group, without either gradual dilatation
or rapid secondary expansion. Light microscopy revealed
minimal disruption of the elastic media immediately and up
to 3 days after aortic perfusion in both the elastase-perfused
and control groups, and each group exhibited early infiltra-
tion of inflammatory cells into the outer aortic wall (Fig 1,
B). In the elastase-perfused group, these initial structural
changes were followed at later time intervals by progressive
transmural aortic wall infiltration by mononuclear phago-
cytes and destruction of the elastic lamellae; in contrast, the
acute inflammatory response in the control group was
resolved by day 7, and the elastic lamellae were structurally
intact at later intervals. The temporal progression of aneu-
rysm development and the sequence of histologic changes
observed were therefore consistent with previous studies
using the elastase-induced mouse model of AAAs. This
emphasizes the close associations among the delayed onset
of chronic aortic wall inflammation, progressive degrada-
tion of medial elastin, and aneurysmal dilation.12,16 These
findings also demonstrate that the time intervals selected
for gene expression analysis were pathophysiologically rel-
evant in the stepwise progression of experimental AAAs.
Alterations in aortic wall gene expression at various
intervals after elastase perfusion compared with normal
aorta. In the initial data analysis, differences in aortic wall
gene expression were examined between normal aorta and
the tissues obtained at each interval from the elastase-
perfused and control groups. There were 336 of 1181
genes expressed at significantly altered levels for at least 1
time interval after elastase perfusion, 135 were altered at
more than 1 interval, and 14 were altered at all 4 intervals
(Table B, online only). Table I indicates the genes with the
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fusion (all 20-fold or 50-fold compared with normal
aorta); the temporal patterns of expression for selected
genes are shown in Figs 2 and 3. A complete list of these
genes is provided in Table C (online only).
Alterations in the heat-inactivated elastase control
group compared with normal aorta. Comparisons be-
tween normal aortas and the control group revealed that
376 of 1181 genes were expressed at significantly different
levels for at least 1 time interval after perfusion with heat-
inactivated elastase, 146 were altered at more than 1 inter-
val, and 10 were altered at all 4 intervals (Tables B and D,
online only). This included 62 genes with synchronous
changes in aortic wall expression in both the elastase and
control groups compared with normal aorta, thus indicat-
ing that they represent common patterns of response to
injury rather than alterations unique to elastase-induced
Fig 1. Aortic dilatation and structural changes during
rysms (AAAs). A, Percentage of aortic dilatation at vari
elastase (controls). Data shown reflect the mean  SE
horizontal line. *P  .001, elastase vs controls, Mann-W
obtained at various intervals after perfusion with elastas
Gieson; original magnification, 40).aneurysm development (Tables B and E, online only).Differential gene expression between the elastase
and control groups. In the second stage of data analy-
sis, temporal differences in gene expression unique to the
development of elastase-induced AAAs were examined
by directly comparing data between animals undergoing
perfusion with elastase vs heat-inactivated elastase con-
trols at each time interval. Significantly different levels of
expressionwere detected for 384of 1181genes during at least
1 time interval after aortic perfusion, with 85 at more than 1
interval and 17 at 3 intervals (Table B, online only). Tran-
scripts with the most pronounced differential increases (20-
fold) and decreases (-50-fold) are shown in Tables II
and Table III, respectively, and the complete list of genes
with differential expression is shown in Table F (online
only).
It is noteworthy that this analysis revealed prominent
differential expression for many genes in the following
evelopment of elastase-induced abdominal aortic aneu-
ntervals after perfusion with elastase or heat-inactivated
e threshold for definition of AAAs is indicated by the
y test. B, Representative sections of mouse aortic tissue
eat-inactivated elastase (controls) (stain, Verhoeff–vanthe d
ous i
. Th
hitne
e or hfunctional categories:
yData
NCBI
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(IL)-1 (Fig 2, B), monocyte chemotactic protein
(MCP)-3 (Fig 2, C), MIG (Fig 2, G), and suppressor of
Table I. Genes with pronounced alterations in aortic wall
normal aorta (partial list)
Increased  20-Fold vs Normal
Elastase Day 3 Fold
interleukin-6 (16193) 61
G1/S-specific cyclin E2 (12448) 473
interleukin-1 beta (16176) 291
osteopontin (20750) 211
ephrin receptor B2 (13844) 192
CD14/LPS receptor (12475) 59
integrin beta-2/CD18 (16414) 37
P-selectin GP ligand 1 (20345) 30
frizzled-related sequence 3 (20378) 30
semaphorin J (20354) 211
gelatinase B (17395) 29
paired box protein-2/PAX2 (18504) 26
serine protease inhibitor 2-2 (20716) 26
basic HLH mesoderm post 2 (17293) 24
anterior-restricted homeobox (15209) 22
CDK interacting CIP1/WAF1 (12575) 22
SOCS-3 (12702) 21
Elastase Day 7 Fold
interleukin-1 beta (16176) 259
osteopontin (20750) 161
brachiury T-box gene (20997) 47
octamer-binding 6 (18991) 33
P-selectin GP ligand 1 (20345) 32
semaphorin J (20354) 32
NIMA-related (18005) 30
c-fgr proto-oncogene (14191) 26
tolloid-like protein (21892) 26
interferon beta (15977) 25
del. in colorectal carcinoma (13176) 25
bub1B mitotic checkpoint (12236) 23
Elastase Day 10 Fold
G1/S-specific cyclin E2 (12448) 784
glutamate receptor epsilon 1 (14811) 329
osteopontin (20750) 30
prepro-orexin (15171) 166
serine protease inhibitor 2-2 (20716) 63
frizzled-related sequence 3 (20378) 34
integrin beta-2/CD18 (16414) 31
myb-related protein B (17865) 28
Rab-3b (69908) 27
IGF-binding protein 1 (16006) 24
del. in colorectal carcinoma (13176) 23
Elastase Day 14 Fold
interleukin-1 beta (16176) 201
YY1 transcription factor (22632) 185
osteopontin (20750) 112
serine protease inhibitor 2-2 (20716) 49
P-selectin GP ligand 1 (20345) 35
semaphorin J (20354) 34
ShcC adaptor (20418) 30
CD14/LPS receptor (12475) 30
Analysis of the expression profiling dataset was used to initially identify significa
compared to normal aorta. The significance threshold for data analysis was set a
calculated relative fold-changes. Genes shown here include those with increased
to normal aorta, excluding genes with synchronous alterations in the elastase
alterations in expression following elastase perfusion is shown in Supplementar
Entrez Gene database at the National Center for Biotechnology Information (cytokine signaling 1.2. Proteinases and protease inhibitors—increases for
urokinase and granzyme C and decreases for anti-
leukoproteinase 1, protease inhibitor 17, prothrom-
ession at various intervals following perfusion elastase vs
Decreased  50-Fold vs Normal
Elastase Day 3 Fold
norepinephrine transporter (20538) 53
K channel (16497) 53
insulin receptor substrate-1 (16367) 56
5-HT receptor-2 (15558) 57
oxytocin receptor (18430) 57
caspase-11 (12363) 59
granzyme B (14939) 61
glutamate receptor delta 1 (14803) 61
CRF receptor (12921) 61
stromelysin-3/MMP-11 (17385) 65
caspase-7 (12369) 71
neuronal death protein 5 (12123) 77
calcium-binding ALG2 (18570) 78
K voltage gated channel (16500) 80
interleukin-converting enzyme (12362) 85
protease inhibitor-17 (20713) 141
Elastase Day 7 Fold
alpha-1-antitrypsin 1-2 (20701) 51
caspase-11 (12363) 65
RalGDSB (19730) 80
guanylate cyclase soluble beta-1 (54195) 81
tubulin beta 4 (22153) 84
interleukin-converting enzyme (12362) 93
connexin 45 (14615) 150
Elastase Day 10 Fold
MAPKK4/JNKK1 (26398) 50
zinc finger protein GLI3 (14634) 51
pou domain class 6F1 (19009) 58
ephrin receptor A7 (13841) 61
eyes absent homolog 1 (EYA1) (14048) 63
hemat. expr. homeobox HHEX (15242) 64
semaphorin E (20348) 112
integrin alpha 7 (16404) 155
Elastase Day 14 Fold
neurogenin 3 (11925) 56
GABA-A receptor alpha-1 (14394) 59
homeobox protein D12 (15432) 59
single-minded homolog 1 (20464) 66
homeobox protein GSH2 (14843) 72
purinergic receptor P2Y (18441) 75
integrin alpha 3 (16400) 80
VIP receptor 2 (22355) 85
oxytocin receptor (18430) 109
cone-rod homeobox (12951) 110
5-HT receptor 1B (15551) 375
rations in aortic wall gene expression at various intervals after elastase perfusion
0.01 using the 2-tailed Z test, and genes were listed in rank-order based on the
ssion of at least 20-fold or decreased expression of at least50-fold compared
at-inactivated elastase control groups (the complete list of genes with distinct
Table C, on-line only). Gene ID numbers (shown in parentheses) refer to the
; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?dbgene).expr
nt alte
t P
expre
and hebin, granzyme B, antithrombin III, plasminogen, 1-
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May 20061014 Van Vickle-Chavez et alFig 2. Temporal expression profiles for selected cytokines, chemokines, adhesion molecules, and cellular receptors.
Relative patterns of expression after aortic perfusion with elastase vs heat-inactivated elastase controls are shown for
selected genes. (A) Interleukin 6 (gene ID 16193), (B) interleukin 1 (gene ID 16176), (C) monocyte chemotactic
protein (MCP)-3 (gene ID 20306), (D)MIP-1 (gene ID 20302), (E)MIP-1 (gene ID 20303), (F)MIP-2 (gene
ID 20310), (G)MIG (gene ID 17329), (H) vascular endothelial growth factor (VEGF)/vascular permeability factor
(VPF) (gene ID 22339), (I) CD14/lipopolysaccharide (LPS) receptor (gene ID 12475), (J) ICAM-1 (gene ID
15894), (K) platelet endothelial cell adhesion molecule (PECAM)-1/CD31 (gene ID 18613), (L) integrin 1 (gene
ID 16412), (M) integrin M (gene ID 16409), (N) endothelial ligand for L-selectin (glycam 1; gene ID 14663), (O)
myeloid cell leukemia differentiation antigen (gene ID 17210), (P) interleukin 1 receptor (gene ID 16177), (Q)
interleukin 2 receptor 	 (gene ID 16186), and (R) urokinase receptor (uPAR; gene ID 18793).
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Volume 43, Number 5 Van Vickle-Chavez et al 1015Fig 3. Temporal expression profiles for selected proteinases, protease inhibitors, extracellular matrix proteins, and
proteins involved in cellular metabolism, stress response, and growth/apoptosis. Relative patterns of expression after
aortic perfusion with elastase vs heat-inactivated elastase controls are shown for selected genes. (A)Gelatinase A/matrix
metalloproteinase (MMP)-2 (gene ID 17390), (B) gelatinase B/MMP-9 (gene ID 17395), (C) dipeptidyl peptidase
I (cathepsin C; gene ID 13032), (D) interleukin-converting enzyme (ICE; gene ID 12362), (E) TIMP-3 (gene ID
21859), (F) cystatin C (gene ID 13010), (G) protease nexin I (gene ID 20720), (H) osteopontin (gene ID 20750),
(I) thrombospondin 1 (gene ID 21825), (J) fibrillin 1 (gene ID 14118), (K) decorin (gene ID 13179), (L) laminin
B2 (gene ID 226519), (M) cyclin E2 (gene ID 12448), (N) hypoxia-inducible factor (HIF)-1 (gene ID 15251), (O)
heat shock protein 84 (gene ID 15516), (P) glutathione-S-transferase 5 (GST-5; gene ID 14863), (Q) apolipoprotein
E (gene ID 11816), and (R) vimentin (gene ID 22352).
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3, D).
3. Adhesion proteins and receptors—decreases for cad-
herin 8, cadherin 15, estrogen-related receptor , inte-
grin 2, and endothelial ligand for L-selectin (Fig 2,N).
4. Extracellular matrix proteins—increases for osteopontin
(Fig 3, H) and fibrillin 1 (Fig 3, J) and decreases for
collagen 91.
5. Proteins involved in immune response—decreases for
T-cell activation antigen CD27, V(D)J recombination
activating protein RAG-1, and T-cell linker ZAP-70.
6. Proteins involved in metabolism, oxidative stress, and
cell growth/apoptosis—increases for the abl proto-
oncogene, c-myc proto-oncogene, fibroblast growth
factor 9, caspase-activated deoxyribonuclease, BAX,
Table II. Genes with the largest differential increases ( 2
perfusion with elastase vs heat-inactivated elastase controls
Day 3 After Aortic Perfusion Fold
p44-MAPK/ERK1 (26417) 589
osteopontin (20750) 575
abl proto-oncogene (11350) 550
c-myc proto-oncogene (17869) 525
BAX protein alpha (12028) 380
cdk-inhibitor kip2 (12577) 275
ephrin receptor A7 (13841) 269
ezrin (22350) 269
myo. dyst. assoc. DMAHP (20475) 263
fibrillin 1 (14118) 200
wingless-related WNT6 (22420) 200
MCP-3 (20306) 195
fos-related antigen-2/FRA2 (14284) 138
Rb binding protein-6 (19647) 102
SMAD3 (17127) 87
distal-less homeobox-6 (13396) 87
interleukin-1 beta (16176) 83
SOCS-1 (12703) 83
adenosine A3 receptor (11542) 78
DNA ligase I (16881) 76
fibroblast growth factor-9 (14180) 74
urokinase/uPA (18792) 74
activin type IIA receptor (11480) 72
cytokeratin-19 (16669) 69
heat shock transc. factor 2 (15500) 66
monocarboxylate transporter (20501) 63
adenosine A2A receptor (11540) 58
Ca-activated K channel beta (16533) 56
Rab GDI alpha (14567) 54
LIM domain kinase 1 (16885) 50
ick proto-oncogene (16818) 49
cdc25MM (19417) 36
apolipoprotein E (11816) 24
Day 7 After Aortic Perfusion Fold
calpactin I light chain (20194) 335
osteoblast-specific OSF2 (50706) 316
HIF-1 alpha (15251) 275
apolipoprotein E (11816) 275
btb & cnc homolog 1 (12013) 263
Analysis of the expression profiling dataset was used to identify significant d
perfusion groups compared to controls. The significance threshold for dat
rank-order based on the calculated relative fold-changes. Genes shown here
compared to the heat-inactivated elastase control group (the complete lis
Supplementary Data Table F, on-line only).BAD, apolipoprotein E (Fig 3, Q), and hypoxia-induc-ible factor 1 (Fig 3, N) and decreases for ataxia telan-
giectasia mutated and caspase 11.
DISCUSSION
In this study, we applied cDNA expression profiling
to an inducible mouse model of experimental AAAs to
better understand the molecular changes that occur dur-
ing aneurysm development. Our study is therefore sim-
ilar in design to that recently reported by Yajima et al,18
in which cDNA microarrays were used to examine aortic
wall gene expression in the elastase-induced rat model of
AAAs. The most significant findings of this study are as
follows: (1) experimental AAAs are associated with an
early increase in expression of genes involved in the
acute-phase innate immune response, leukocyte recruit-
ld) in aortic wall expression at various intervals following
Day 7 After Aortic Perfusion (Cont) Fold
NIMA-related protein kinase-2 (18005) 182
huntingtin-associated protein 1 (15114) 138
glucocorticoid receptor 1 (14815) 117
cytokeratin 14 (16664) 102
Day 10 After Aortic Perfusion Fold
clusterin/apolipoprotein J (12759) 355
purine-rich binding A/PURA (19290) 295
int-3 proto-oncogene/notch4 (18132) 219
MAPKK3/MEK3 (26406) 162
acetylcholine receptor delta (11447) 135
gIFN-induced monokine MIG (17329) 117
homeobox protein 3.1 (15426) 93
secreted apoptosis-related prot. 1 (20319) 79
interferon regulatory factor 1 (16362) 72
p18 ckd inhibitor INK6 (12580) 51
follistatin (14313) 48
zinc finger protein 144 (22658) 44
Ca-activated K channel beta (16533) 44
protein kinase C theta (18761) 42
Marcks-related protein (17357) 23
Day 14 After Aortic Perfusion Fold
gut Kruppel-like factor (16600) 513
granzyme C (14940) 437
nucleoside diphosphate kinase B (18103) 437
transferrin receptor (22042) 398
mdm2 (17246) 347
zinc transporter-4 (22785) 282
caspase-activated DNase (13368) 240
huntingtin-associated protein 1 (15114) 174
special AT-rich binding 1 (20230) 138
apolipoprotein E (11816) 91
formin-4 (14260) 76
semaphorin E (20348) 74
prepro-endothelin-3 (13616) 68
BAD protein (12015) 66
STRA13 (16792) 65
phenylalanine-4-hydroxylase (18478) 50
guanine nucl. binding alpha, stim. (14683) 32
disabled homolog 2 (13132) 22
nces in aortic wall gene expression at various intervals between the elastase
sis was set at P  0.01 using the 2-tailed Z test, and genes were listed in
de those with increased expression of at least 20-fold in the elastase group
enes with differential expression following elastase perfusion is shown in0-fo
iffere
a analy
inclu
t of gment, and the transition to chronic inflammation; (2)
t of g
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distinct patterns of increased expression for a variety of
matrix-degrading proteinases, including MMPs, cathep-
Table III. Genes with the largest differential decreases (
following perfusion with elastase vs heat-inactivated elastas
Day 3 After Aortic Perfusion Fold
androgen receptor (11835) 50
gem induced immed. early (14579) 50
oxytocin receptor (18430) 55
neural CAM-2 (17968) 58
ack tyrosine-protein kinase (51789) 60
antileukoproteinase-1 (20568) 66
K voltage gated channel (16500) 66
caspase-11 (12363) 69
T-cell activation CD27 (21940) 69
tryptophan 5-hydroxylase (21990) 71
interleukin-6 receptor alpha (16194) 71
NIMA-rel. protein kinase 3 (23954) 76
V(D)J recomb. activ. RAG-1 (19373) 79
collagen 9 alpha-2/COL9A2 (12840) 81
src-related intestinal kinase (20459) 83
alpha 2 catenin (12386) 83
galanin receptor 1 (14427) 87
unconventional myosin VI (17920) 87
glutamate receptor alpha 1 (14799) 87
BMP receptor type 1B (12167) 89
mem. metalloendopeptidase (17380) 89
T-cell transcription GATA3 (14462) 91
protease inhibitor-17 (20713) 93
interleukin-converting ICE (12362) 93
zinc transporter-4 (22785) 93
L-selectin ligand glycam-1 (14663) 93
cadherin-8 (12564) 95
purinergic receptor P2Y (18441) 98
prothrombin (14061) 102
GABA-A receptor alpha-1 (14394) 102
norepinephrine transporter (20538) 107
photolyase (12952) 107
myelin-assoc. basic protein (17433) 110
neuroendocrine convertase-2 (18549) 112
ataxia telangiectasia/ATM (11920) 115
5-HT receptor-2 (15558) 117
granzyme B (14939) 123
CRH receptor 2 (12922) 123
estrogen-rel. receptor alpha (26379) 126
antithrombin III (11905) 132
secretogranin V (20394) 148
prepro-orexin (15171) 162
Day 7 After Aortic Perfusion Fold
cdc25MM (19417) 55
integrin alpha-2/CD49b (16398) 56
LIM domain kinase-1 (16885) 58
cytokeratin-18 (16668) 59
antileukoproteinase-1 (20568) 60
tubulin beta-4 (22153) 62
AP endonuclease-1 (11792) 65
Rab-3b (69908) 65
SchC adaptor (20418) 66
CAM kinase-GR (12326) 68
collagen 9 alpha-1/COL9A1 (12839) 69
prothrombin (14061) 72
Analysis of the expression profiling dataset was used to identify significant d
perfusion groups compared to controls. The significance threshold for dat
rank-order based on the calculated relative fold-changes. Genes shown here
compared to the heat-inactivated elastase control group (the complete lis
Supplementary Data Table F, on-line only).sins, and serine proteinases; (3) at all time intervals ofaneurysm development, there is a particularly marked
increase in expression for genes encoding matricellular
glycoproteins not previously associated with aneurysm
-fold) in aortic wall expression at various intervals
trols
Day 7 After Aortic Perfusion Fold
prothrombin (14061) 72
bub1 mitotic checkpoint kinase (12235) 74
tyrosine receptor kinase TRK-B (18212) 74
plasminogen precursor (18815) 76
c-Src-kinase and neg. regulator (12988) 76
homeobox protein HOX-8 (17702) 78
alpha-1 antitrypsin 1-2 (20701) 79
interleukin-converting ICE (12362) 81
ack tyrosine-protein kinase (51789) 83
kinesin motor protein C2 (16581) 83
zinc finger protein 144 (22658) 89
semaphorin N (20359) 91
proteasome component C8 (19167) 98
GTPase-activating protein III (19414) 107
homeobox protein D3 (15434) 123
caspase-11 (12363) 123
adenosine A3 receptor (11542) 132
ACh receptor-assoc. RAPSYN (19400) 132
Day 10 After Aortic Perfusion Fold
transcription factor 3G (15377) 60
chromobox homolog-4/CBX4 (12418) 62
NIMA-rel. protein kinase 3 (23954) 72
caudal type homeobox-2/Cdx2 (12591) 76
zinc finger protein GLI3 (14634) 91
homeobox protein D10 (15430) 91
ephrin receptor A4 (13838) 91
pou domain class 6F1 (19009) 95
ephrin receptor A7 (13841) 105
inhibin beta E (16326) 105
semaphorin E (20348) 107
G2/M-specific cyclin G2 (12452) 110
filensin (12075) 120
T cell activation linker ZAP-70 (16797) 126
retinoic acid receptor gamma (20183) 129
myosin light chain 1 atrial/fetal (17896) 158
LIM homeobox protein 3 (16871) 174
eyes absent homolog-1/EYA1 (14048) 178
cadherin-15 (12555) 195
TNF receptor-assoc.-4/TRAF4 (22032) 209
Day 14 After Aortic Perfusion Fold
mesenchyme homeobox-2 (17286) 58
L-myc proto-oncogene (16918) 98
cadherin-15 (12555) 112
G2/mitotic-specific cyclin B1 (268697) 115
homeobox protein D12 (15432) 123
A-myb proto-oncogene (17864) 141
galanin receptor 1 (14427) 158
nociceptin (18155) 162
N-myc proto-oncogene (18109) 195
ephrin A3 (13638) 204
G2/M-specific cyclin A2 (12428) 204
GABA-A receptor alpha-1 (14394) 219
5-HT receptor 1B (15551) 257
neurogenin-3 (11925) 269
cone-rod homeobox (12951) 295
nces in aortic wall gene expression at various intervals between the elastase
sis was set at P  0.01 using the 2-tailed Z test, and genes were listed in
de those with decreased expression of at least 50-fold in the elastase group
enes with differential expression following elastase perfusion is shown in50
e con
iffere
a analy
includisease, such as osteopontin, thrombospondin (TSP)-1,
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a decreased pattern of expression for genes encoding
several different proteinase inhibitors, regulators of oxi-
dative stress, and markers of smooth muscle cell func-
tion.
Recruitment and activation of inflammatory cells.
Our findings confirm the suspicion that many genes in-
duced during the early phases of elastase-induced aneurysm
development are involved in inflammatory cell recruitment
and activation. This included genes that encode acute phase
reactants and leukocyte markers expressed at peak levels
within 3 days of elastase perfusion, such as IL-6 (Fig 2, A),
IL-1 (Fig 2, B), CD14/lipopolysaccharide receptor (Fig
2, I), integrin L/CD11a, and integrin M/CD11b (Fig
2, M). IL-6 is of particular interest because it is overex-
pressed in human AAA tissues and because circulating levels
of IL-6 are increased in patients with AAAs.19-22 This has
led to the suggestion that IL-6 might act to induce the
expression of extracellular matrix proteinases by mononu-
clear phagocytes and other cell types within aneurysm
tissue, thereby serving as a proximal mediator of aneurys-
mal degeneration. Indeed, in recent studies we have found
that elastase-induced aneurysms are associated with a sub-
stantial increase in IL-6 protein concentrations, both in
aortic tissue and in the circulation, and that these levels are
lower during pharmacologic suppression of AAAs.16 These
observations thereby provide strong evidence that the re-
sults obtained here for IL-6 expression are also reflected at
the protein level in this model of AAAs.
Genes encoding several different chemokines were in-
duced early after elastase perfusion (peak levels between day
3 and day 7), including MCP-3 (Fig 2, C), MIP-1 (Fig 2,
D), MIP-1 (Fig 2, E), and MIP-2 (Fig 2, F). The proteins
encoded by these genes are part of a structurally related
family that exhibits chemotactic activity for mononuclear
phagocytes.23 Although the generation of high local con-
centrations of elastin degradation products is considered in
large part responsible for stimulating the inflammatory cell
response observed in elastase-induced AAAs, an early in-
crease in medial smooth muscle cell expression of C-C
chemokines (MCP-1 and regulated on activation, T cells
expressed and secreted) indicates that these molecules may
also play a role in establishing a chronic inflammatory
response in the elastase-injured aorta.24 This potential
mechanism is further reinforced by the role of C-C chemo-
kines in the formation of suprarenal aortic aneurysms in
hypercholesterolemic mice.25
The expression patterns of MCP-3, MIP-1, MIP-1,
and MIP-2 were all relatively similar but were different
from the pattern exhibited by MIG, a C-X-C chemokine
induced primarily at later stages of aneurysm formation
(peak expression on day 14; Fig 2, G). Because MIG has
prominent chemotactic activity for monocytes and because
it was induced primarily during the late period of acceler-
ated aortic dilatation, this chemokine may have a special
role in sustaining and amplifying the chronic inflammatory
response. The induction ofMIGmay also reflect a T-helper
type 1 cellular immune response in elastase-induced AAAs,similar to that observed in the calcium chloride–induced
mouse model of AAAs.26 This may help to explain how
elastase perfusion results in leukocyte recruitment into the
outer aortic wall. It will therefore remain necessary to
identify the cell types and mechanisms responsible for pro-
duction of MIG and other chemokines within the elastase-
injured aorta, as well as their functional importance in
aneurysmal degeneration.
Matrix-degrading proteinases. Enzymatic degrada-
tion of structural extracellular matrix proteins is a key
pathophysiologic process in aneurysmal degeneration. It is
notable that among the matrix-degrading proteinases ex-
amined in this study, the expression of gelatinase
A/MMP-2 was not significantly altered from the normal
aorta or the control group at day 3 but progressively
increased at later intervals when the increase in aortic
diameter was most pronounced (Fig 3, A). Gelatinase
B/MMP-9 exhibited a different pattern, with marked in-
duction by day 3 and relatively diminished expression at
later time intervals, but its expression was similar at all
intervals between the elastase and control groups (Fig 3, B).
A third pattern was observed for expression of MT1-
MMP/MMP-14, which peaked on day 7 and increased
again on day 14 but was also not significantly different at
any interval between the elastase and control groups. Al-
though each of these MMPs is also expressed in human
aortic aneurysms, their temporally distinct patterns of ex-
pression in elastase-induced AAAs suggest that they may
exert different roles in the stepwise progression of AAAs.
Indeed, gene-targeting studies have revealed that MMP-9
(but not MMP-2) is required for development of elastase-
induced AAAs,12 whereas deficiency in either MMP-9 or
MMP-2 results in suppression of calcium chloride–induced
AAAs.27
We found that the early stages of aneurysm develop-
ment were associated with a marked increase in the expres-
sion of dipeptidyl peptidase I (DPPI; cathepsin C), with a
secondary increase at later phases of aneurysm expansion
(Fig 3, C). The increase in DPPI was accompanied by a
coincident decrease in expression of cystatin C, the princi-
pal endogenous inhibitor of cysteine proteases (Fig 3, F).
This observation is of special interest given that DPPI can
degrade extracellular matrix proteins and that circulating
cystatin C levels are decreased in patients with both athero-
sclerosis and aortic aneurysms.28,29 Further studies are
therefore needed to elucidate the functional role of DPPI
and other cysteine proteases in aneurysmal degeneration.
Matricellular glycoproteins. One of the important
findings from this study is themarked increase in expression
for several genes encodingmatricellular glycoproteins, such
as osteopontin and TSP-1. This finding suggests that they
may help orchestrate tissue repair processes in the injured
vascular wall. Thus, osteopontin increased more than 200-
fold compared with normal aorta as early as 3 days after
elastase perfusion (and 575-fold greater than the control
group), and it remained substantially increased thereafter
(Fig 3, H). Osteopontin is a multifunctional protein in-
volved in the regulation of developmental osteogenesis,
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response and has been shown to have a prominent role in
cardiovascular injury and disease.30,31 Osteopontin binds
to interstitial and basement membrane collagens, as well as
fibronectin,32 and it acts as an adhesion substrate for cell
migration through interactions with both v3 integrin
and the hyaluronan receptor CD44.33,34 Osteopontin de-
ficiency is associated with reduced collagen deposition and
enhanced left ventricular dilatation after myocardial infarc-
tion, as well as attenuation of angiotensin-induced supra-
renal aortic aneurysms, in hypercholesterolemic mice.35,36
It will therefore be of great interest to test the hypothesis
that osteopontin might also play a critical role in the
elastase-induced mouse model of AAAs.
TSP-1 expression increased steadily during the devel-
opment of aneurysmal degeneration, and maximal levels
were reached by day 14 (Fig 3, I)—a significant pattern
suggesting that this matricellular glycoprotein also partici-
pates in experimental AAA formation. TSP-1 potentially
mediates a wide spectrum of complex functions in the vessel
wall, where it is secreted by several different types of cells,
including endothelium, vascular smooth muscle, and mac-
rophages.37-39 TSP-1 interacts with matrix proteins, as well
as cell-surface receptors and adhesionmolecules; moreover,
it enhances smooth muscle cell proliferation and migration
and platelet activation.40,41 Additionally, TSP-1 is known
to activate T lymphocytes, and its presence has been docu-
mented in human atheromatous lesions and experimental
models of acute vascular injury and intimal hyperplasia.42,43
A potential role for this protein in regulating the formation
of aneurysms has yet to be explored.
Regulation of oxidative stress. Decreased expression
in experimental AAAs may also yield clues as to the role of
specific gene products in aneurysm formation. For exam-
ple, glutathione-S-transferase 5 (Fig 3, P) belongs to a
family of proteins that afford cellular protection against
oxidative stress and toxins.44 Oxidative stress can cause
direct cellular injury, as well as the expression of vascular
inflammatory gene products, and alterations in glutathione-S-
transferases have been documented in human atherosclerotic
disease.45,46 The relative decrease in glutathione-S-transferase
5 messenger RNA observed throughout aneurysm develop-
ment, therefore, indicates the potential relevance of oxidative
stress in this murine model of AAAs. It is important to note
that this observation is similar to the results obtained by
Yajima et al,18 thus supporting a general role for oxidative
stress in aneurysm formation.
Limitations. The results of this study must clearly be
taken in the context that despite many similarities, the
pathophysiology of degenerative human AAAs may differ
from the elastase-induced lesions observed in the labora-
tory. It is also important to reiterate that the development
of elastase-induced AAAs is a dynamic process character-
ized by ongoing changes in aortic wall cellular composi-
tion, distribution, and number. Temporal changes in aortic
wall gene expression therefore reflect the various cell types
present, as well as the transcriptional activity for a given
gene within a given cell population, and it remains to bedetermined whether the altered levels of expression for
specific genes are due to changes in either resident aortic
wall cell types (endothelium, medial smooth muscle, and
fibroblasts), polymorphonuclear neutrophils recruited early
and transiently in the response to the perfusion injury, or
chronic inflammatory cells that appear later in the course of
aneurysmal degeneration (monocyte-derived tissue macro-
phages, T cells, and B lymphocytes). Bonemarrow–derived
(CD34
) circulating progenitor cells may also contribute
to this process after mobilization and recruitment into the
aortic wall.47
As in any expression profiling study, measures of rela-
tive tissue messenger RNA expression obtained with mi-
croarrays require further confirmation by other techniques
before more functional studies are performed. Moreover,
changes in messenger RNA are not always reflected by
similar changes in protein production, and posttransla-
tional modifications in protein are often just as crucial in
regulating cellular behavior as are changes in gene tran-
scription. Interpretation of large-scale cDNA expression
data is further complicated by the large number of alter-
ations typically observed for intracellular signaling proteins,
transcription factors, and gene homologues with unknown
function in mammalian systems.
Finally, it is difficult to anticipatewhichof the genes found
to be differentially expressed in this study will be proven to be
functionally significant in the process of aortic response to
injury, inflammation, matrix remodeling, and aneurysmal de-
generation. Knowledge of these temporal gene expression
profiles will nonetheless be helpful in guiding further studies
on the molecular mechanisms underlying aneurysmal degen-
eration andwill be especially valuable for investigations involv-
ing mice with specific genetic alterations.
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